Through a comprehensive evaluation of the efficacy of mTC1 and mTC3, we validated their potential as therapeutic agents and gained a deeper understanding of the MMP-TIMP role within the GBM microenvironment. This evidence concerns the gene TIMP1 and glioblastoma.